Clinical Trials Logo

Fra(X) Syndrome clinical trials

View clinical trials related to Fra(X) Syndrome.

Filter by:
  • None
  • Page 1

NCT ID: NCT04869930 Recruiting - Clinical trials for Autism Spectrum Disorder

Establishing a Diagnostic and Therapeutic Index in Autism Spectrum Disorder (ASD) and Fragile X Syndrome

Start date: November 1, 2021
Phase:
Study type: Observational

The purpose of this study is to accumulate and quantitatively analyze data on the microbiome, serotonin signaling and genetics, and inflammatory cytokines from patients with Autism Spectrum Disorder and Fragile X Syndrome. Computational analysis of multi-dimensional datasets will be used to establish a "Diagnostic and Therapeutic Index" - an objective set of tools that can help differentiate subtypes of Autism Spectrum Disorder and develop more accurate methods of diagnosis and response to treatment.

NCT ID: NCT03862950 Recruiting - Clinical trials for Intellectual Disability

A Trial of Metformin in Individuals With Fragile X Syndrome (Met)

Start date: May 24, 2019
Phase: Phase 2
Study type: Interventional

This study is a controlled trial of metformin in individuals with fragile X syndrome between the ages of 6 and 35 years. Participants will be randomized in a double-blind design to either drug or placebo and will attend three visits to the study site in a 4-month period for a series of tests. The primary objectives are to assess safety, tolerability, and efficacy of metformin in the treatment of language deficits, behavior problems, and obesity/excessive appetite in individuals with fragile X syndrome.

NCT ID: NCT03569631 Completed - Fragile X Syndrome Clinical Trials

A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome

Start date: July 9, 2018
Phase: Phase 2
Study type: Interventional

This is a single-center, randomized, double-blind, 2-period crossover study to explore the effects of BPN14770 on cognitive function and behavior in subjects with Fragile X Syndrome. Subjects will receive both active treatment with BPN14770 capsules and matching placebo capsules in the course of the study. One treatment will be administered during each of the 12-week study periods.

NCT ID: NCT03479476 Completed - Clinical trials for Intellectual Disability

A Trial of Metformin in Individuals With Fragile X Syndrome

Met
Start date: April 30, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

This study is a controlled trial of metformin in individuals with fragile X syndrome between the ages of 6 and 25 years. Participants will be randomized in a double-blind design to either drug or placebo and will attend three visits to the study site in a 4-month period for a series of tests. The primary objectives are to assess safety, tolerability, and efficacy of metformin in the treatment of language deficits, behavior problems, and obesity/excessive appetite in individuals with fragile X syndrome.